|
|
Exact Sciences Corporation (NASDAQ: EXAS) |
|
Price: $104.9100
$1.04 
1.001%
|
| Day's High:
| $104.98
| Week Perf:
| 1.02 %
|
| Day's Low: |
$ 104.90 |
30 Day Perf: |
1.57 % |
| Volume (M): |
21,562,100 |
52 Wk High: |
$ 104.98 |
| Volume (M$): |
$ 2,262,080 |
52 Wk Avg: |
$86.01 |
| Open: |
$104.93 |
52 Wk Low: |
$51.75 |
|
|
| Market Capitalization (Millions $) |
19,795 |
| Shares
Outstanding (Millions) |
189 |
| Employees |
7,200 |
| Revenues (TTM) (Millions $) |
3,245 |
| Net Income (TTM) (Millions $) |
-208 |
| Cash Flow (TTM) (Millions $) |
349 |
| Capital Exp. (TTM) (Millions $) |
135 |
Business Description
Exact Sciences Corporation is a medical technology company headquartered in Madison, Wisconsin, that is focused on developing and commercializing diagnostic tests for the early detection and prevention of cancer. Founded in 1995, the company has risen to prominence as a leader in the field of molecular diagnostics, a branch of medicine that uses DNA and RNA analysis to identify and diagnose diseases.
The company's flagship product is Cologuard, a non-invasive, at-home fecal immunochemical test (FIT) for colorectal cancer screening. Cologuard uses advanced DNA and protein analysis to detect signs of colorectal cancer and precancerous growths, offering patients a comfortable and convenient alternative to traditional colonoscopies. Since its launch in 2014, Cologuard has become one of the most widely used and highly rated colorectal cancer screening tests in the United States.
In addition to Cologuard, Exact Sciences also offers a suite of other diagnostic products for cancer detection, including Oncotype DX, a genomic test for breast, colon, and prostate cancer; and ThyraMIR, a thyroid cancer test that uses microRNA analysis to detect malignant nodules.
The company has a strong commitment to research and development, with a dedicated team of scientists working to develop new diagnostic tests and improve existing products. In addition to its proprietary diagnostic platforms, Exact Sciences has also formed strategic partnerships with other leading medical technology companies to expand its capabilities in areas such as liquid biopsy and precision medicine.
As of 2021, Exact Sciences has grown to become a multi-billion-dollar company with more than 6,000 employees worldwide. The company has received numerous awards and accolades for its innovative products and commitment to improving healthcare outcomes, and is widely regarded as a leader in the field of molecular diagnostics.
Company Address: 5505 Endeavor Lane Madison 53719 WI
Company Phone Number: 284‑5700 Stock Exchange / Ticker: NASDAQ EXAS
|
|
|
|
|
|
|
| Stock Performances by Major Competitors |
|
|
|
| Business Update
Published Fri, Nov 7 2025 3:00 PM UTC
MADISON, Wis. Exact Sciences Corp. (NASDAQ: EXAS), a recognized leader in the field of cancer screening and diagnostic tests, has announced unprecedented results from its landmark ALTUS study (NCT: 05064553). These pivotal clinical validation findings highlight the significant potential of the company’s Oncoguard Liver blood test in transforming the early detection of h...
|
| Business Update
Published Wed, Sep 10 2025 1:00 PM UTC
Exact Sciences Launches Groundbreaking Cancerguard Test: Pioneering Multi-Cancer Early Detection Amidst Revenue GrowthIn a significant advancement within the cancer diagnostics landscape, Exact Sciences Corp. (Nasdaq: EXAS), headquartered in Madison, Wisconsin, has officially launched Cancerguard, a cutting-edge multi-cancer early detection (MCED) blood test. This test is n...
|
| Business Update
Published Wed, Jul 9 2025 5:23 PM UTC
In a significant advancement for colorectal cancer (CRC) patients, Exact Sciences Corp., a leading player in cancer diagnostics, recently announced that its Oncodetect molecular residual disease (MRD) test will now be covered by Medicare. This decision, made through the Centers for Medicare & Medicaid Services (CMS) Molecular Diagnostic Services Program (MolDX), marks a cruc...
|
| Business Update
Published Wed, Jan 22 2025 8:28 AM UTC
Exact Sciences Corp. (Nasdaq: EXAS), a pioneering company in the field of cancer diagnostics, has unveiled compelling clinical data, reaffirming the efficacy of its Oncodetect™ MRD test in detecting molecular residual disease and predicting recurrence in colorectal cancer patients. The data was presented at the esteemed 2025 American Society of Clinical Oncology Gastrointe...
|
| Business Update
Published Fri, Oct 4 2024 10:47 AM UTC
A New Era in Colorectal Cancer Screening: The FDA s Approval of Exact Sciences Cologuard Plus In a landmark decision, the U.S. Food and Drug Administration (FDA) has bestowed its approval upon Exact Sciences Corp. s newest innovation, the Cologuard Plus test. This FDA endorsement marks a significant milestone in the evolution of non-invasive colorectal cancer screenings. Ex...
|
Fundamental Analysis
| Per Share |
Current |
| Earnings (TTM) |
-1.11 $ |
| Revenues (TTM) |
17.2 $
|
| Cash Flow (TTM) |
1.85 $ |
| Cash |
5.11 $
|
| Book Value |
12.72 $
|
| Dividend (TTM) |
0 $ |
| Efficiency
|
Current |
| Revenue per Employee
(TTM) |
450,738 |
| Net
Income per Employee (TTM) |
-28,882 |
| Receivable Turnover Ratio (TTM) |
10.49 |
| Inventory Turnover Ratio (TTM) |
5.8 |
| Asset Turnover Ratio (TTM) |
0.56 |
|
|
| Per Share |
|
| Earnings (TTM) |
-1.11 $
|
| Revenues (TTM) |
17.2 $ |
| Cash Flow (TTM) |
1.85 $ |
| Cash |
5.11 $
|
| Book Value |
12.72 $ |
| Dividend (TTM) |
0 $ |
|
|
| |
| Screening |
|
 78.39 % |
of total Revenue |
| Screening Medicare Parts B C |
|
29.1 % |
of total Revenue |
| Screening Commercial |
|
41.75 % |
of total Revenue |
| Screening Other |
|
7.53 % |
of total Revenue |
| Precision Oncology |
|
21.71 % |
of total Revenue |
| Precision Oncology Medicare Parts B C |
|
5.99 % |
of total Revenue |
| Precision Oncology Commercial |
|
5.93 % |
of total Revenue |
| Precision Oncology International |
|
6.92 % |
of total Revenue |
| Precision Oncology Other |
|
2.87 % |
of total Revenue |
| United States |
|
93.18 % |
of total Revenue |
| Outside of United States |
|
6.92 % |
of total Revenue |
| |
On January 13 2025 the Exact Sciences provided following guidance
Exact Sciences Corporation has released preliminary financial results for the fourth quarter of 2024, offering insight into the company's strong performance. According to their latest projections, the corporation anticipates generating revenue of approximately $713 million for the period that concluded on December 31, 2024.
Based in Madison, Wisconsin, Exact Sciences Corp. (Nasdaq: EXAS) is recognized as a frontrunner in the field of cancer screening and diagnostic testing. The Exact Sciences team achieved remarkable results as we wrapped up 2024, positioning us for continued growth and profitability in the future, stated Kevin Conroy, the chairman and CEO of the company. We are eager to broaden our...
|
|
|
3.8%